Ignite Creation Date:
2024-05-06 @ 3:31 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04669444
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-01-26
First Post:
2020-12-09
Brief Title:
Biomarkers Genomics Physiology in Critically Ill and ECMO Patients
Sponsor:
University of California San Diego
Organization:
University of California San Diego
Study Overview
Official Title:
Investigation of Biomarkers Genomics Physiology in Critically Ill and ECMO Patients
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IGNITE
Brief Summary:
Patients in end-stage cardiac failure andor respiratory failure may be started on a rescue therapy known as Extracorporeal Membrane Oxygenation ECMO One of the major clinical questions is how to manage the ventilator when patients are on ECMO therapy Ventilator Induced Lung Injury VILI can result from aggressive ventilation of the lung during critical illness VILI and lung injury such as Acute Respiratory Distress Syndrome ARDS can further increase the total body inflammation and stress this is known as biotrauma Biotrauma is one of the mechanisms that causes multi-organ failure in critically ill patients One advantage of ECMO is the ability to greatly reduce the use of the ventilator and thus VILI by taking control of the patients oxygenation and acid-base status By minimizing VILI during ECMO we can reduce biotrauma and thus multi-organ failure Since the optimal ventilator settings for ECMO patients are not known we plan to study the impact of different ventilator settings during ECMO on patients physiology and biomarkers of inflammation and injury
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None